CD8A and neoplasm: IRE: 0% CR. IRE + TLR3 + TLR9: Superior primary tumor growth inhibition and CD8+ T cell response compared to IRE and IRE + anti-PD-1. IRE + anti-PD-1 + TLR3 + TLR9: 100% CR of treated and non-treated tumors. Increased the tumor infiltration of CD8+ and CD4+ T cells and the CD8+ T cell response compared to IRE alone. Induced a M1/M2 macrophage balance towards the anti-tumor M1 and reduced Tregs and MDSCs. IRE + anti-PD-1 + TLR3 + TLR9: 100% CR of treated tumors.